July 3, 2020
This article was originally published by Healio Once-weekly selinexor, bortezomib and dexamethasone improved outcomes compared with twice-weekly bortezomib and dexamethasone for pretreated multiple myeloma, according to results presented during the ASCO20 Virtual Scientific Program. Findings from the randomized phase 3 BOSTON study showed prolonged PFS and a higher objective response rate in the experimental group....
Continue Reading
This article was originally published by AJMC There are promising signs that chimeric antigen receptor (CAR) T-cell therapies might lead to meaningful advances in the therapy of multiple myeloma. However, investigators will first need to clear a number of key hurdles. Chimeric antigen receptor (CAR) gene-modified T-cell therapy appears to have considerable promise for patients with multiple...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand